Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Wildsmith, Sophie; Li, Weimin; Wu, Song; Stewart, Ross; Morsli, Nassim; Raja, Rajiv; Zhang, Qu; Ye, Jiabu; He, Philip; Shetty, Jagdish; Yovine, Alejandro; Holoweckyj, Nicholas; Real, Katia; Walker, Jill; Wrona, Magdalena; de Los Reyes, Melissa; Barker, Craig; Whiteley, Jessica; Haddad, Robert; Licitra, Lisa; Ferris, Robert; Fayette, Jérôme; Zandberg, Dan P; Siu, Lillian L; Mesía, Ricard

Wildsmith, Sophie; Li, Weimin; Wu, Song; Stewart, Ross; Morsli, Nassim; Raja, Rajiv; Zhang, Qu; Ye, Jiabu; He, Philip; Shetty, Jagdish; Yovine, Alejandro; Holoweckyj, Nicholas; Real, Katia; Walker, Jill; Wrona, Magdalena; de Los Reyes, Melissa; Barker, Craig; Whiteley, Jessica; Haddad, Robert; Licitra, Lisa; Ferris, Robert; Fayette, Jérôme; Zandberg, Dan P; Siu, Lillian L; Mesía, Ricard.

Afiliación

Wildsmith S; AstraZeneca, Cambridge, United Kingdom.
Li W; AstraZeneca, Gaithersburg, Maryland.
Wu S; AstraZeneca, Gaithersburg, Maryland.
Stewart R; AstraZeneca, Cambridge, United Kingdom.
Morsli N; AstraZeneca, Cambridge, United Kingdom.
Raja R; AstraZeneca, Gaithersburg, Maryland.
Zhang Q; AstraZeneca, Gaithersburg, Maryland.
Ye J; AstraZeneca, Gaithersburg, Maryland.
He P; AstraZeneca, Gaithersburg, Maryland.
Shetty J; AstraZeneca, Gaithersburg, Maryland.
Yovine A; AstraZeneca, Cambridge, United Kingdom.
Holoweckyj N; AstraZeneca, Gaithersburg, Maryland.
Real K; AstraZeneca, Cambridge, United Kingdom.
Walker J; AstraZeneca, Cambridge, United Kingdom.
Wrona M; AstraZeneca, Warsaw, Poland.
de Los Reyes M; AstraZeneca, Gaithersburg, Maryland.
Barker C; AstraZeneca, Cambridge, United Kingdom.
Whiteley J; AstraZeneca, Cambridge, United Kingdom.
Haddad R; Dana-Farber Cancer Institute, Boston, Massachusetts.
Licitra L; Head & Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori Milano, University of Milan, Milan, Italy.
Ferris R; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Fayette J; Centre Léon Bérard, Lyon, France.
Zandberg DP; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Siu LL; Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Mesía R; Catalan Institute of Oncology, B-ARGO group, IGTP, Badalona, Spain.

Clin Cancer Res ; 29(11): 2066-2074, 2023 06 01.

Article en En | MEDLINE | ID: mdl-36806911

Asunto(s)

Antineoplásicos Inmunológicos; Neoplasias de Cabeza y Cuello; Neoplasias Pulmonares; Humanos; Antineoplásicos Inmunológicos/uso terapéutico; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Biomarcadores de Tumor/genética; Biomarcadores de Tumor/uso terapéutico; Neoplasias de Cabeza y Cuello/tratamiento farmacológico; Neoplasias de Cabeza y Cuello/genética; Neoplasias Pulmonares/tratamiento farmacológico; Recurrencia Local de Neoplasia/tratamiento farmacológico; Recurrencia Local de Neoplasia/genética; Estudios Retrospectivos; Carcinoma de Células Escamosas de Cabeza y Cuello/tratamiento farmacológico; Carcinoma de Células Escamosas de Cabeza y Cuello/genética; Resultado del Tratamiento

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antineoplásicos Inmunológicos / Neoplasias de Cabeza y Cuello / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google